Sublingual versus subcutaneous buprenorphine in opiate abusers.

  title={Sublingual versus subcutaneous buprenorphine in opiate abusers.},
  author={Donald R. Jasinski and Paul J. Fudala and Rolley E. Johnson},
  journal={Clinical pharmacology and therapeutics},
  volume={45 5},
To compare the pharmacologic profiles of sublingually and subcutaneously administered buprenorphine, 10 healthy male subjects with histories of opiate abuse were given sublingually administered buprenorphine (1, 2, and 4 mg), subcutaneously administered buprenorphine (1 and 2 mg), and placebo in a double-blind, double-dummy, placebo-controlled study. All active buprenorphine dosages produced a significant degree of miosis but no significant changes in body temperature, blood pressure, or… CONTINUE READING